Laser for retina disease goes to trial

Article

Results of a clinical trial investigating Ellex's non-thermal Retina Regeneration Therapy (2RT), demonstrates the therapy's potential to improve and stabilize visual acuity (VA) and reduce retinal oedema in patients with diabetic maculopathy and macular oedema without causing damage to photoreceptors.

Results of a clinical trial investigating Ellex's non-thermal Retina Regeneration Therapy (2RT), demonstrates the therapy's potential to improve and stabilize visual acuity (VA) and reduce retinal oedema in patients with diabetic maculopathy and macular oedema without causing damage to photoreceptors.

The prospective study, being conducted at King's College, University of London, enrolled 18 patients (29 eyes). All patients received treatments with the Ellex 2RT prototype laser and received follow-up examinations at three, six and 12-months.

At three months, the majority of patients demonstrated improvements in VA and central macular thickness (CMT), as measured by optical coherence tomography. CMT decreased in 55% of eyes and remained stable in 24%. An increase in CMT was seen in just 20% of eyes. Furthermore, micro-perimetry confirmed that there was no damage to photoreceptor cells.

Ellex now plans to conduct trials to determine whether the 2RT has potential as an early stage therapy for retinal diseases.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.